Comparative Outcome Between Chemoradiotherapy and Lateral Pelvic Lymph Node Dissection Following Total Mesorectal Excision in Rectal Cancer
Authors:
- Jin C. KimJKJin C. Kim
- Keiichi TakahashiKTKeiichi Takahashi
- Chang S. YuCYChang S. Yu
- Hee C. KimHKHee C. Kim
- Tae W. KimTKTae W. Kim
- Min H. RyuMRMin H. Ryu
- Jong H. KimJKJong H. Kim
- Takeo MoriTMTakeo Mori
- 1 November 2007
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 246 (5) , 754-762
Abstract
To evaluate comparative outcome between adjuvant postoperative chemoradiotherapy (postoperative CRT) and lateral pelvic lymph node dissection (LPLD) following total mesorectal excision (TME) in rectal cancer patients. Although TME results in lower rate of locoregional recurrence compared with conventional surgery, these 2 treatment modalities following TME have not adequately been appraised until the present trend of preoperative chemoradiotherapy. Between 1995 and 2000, patients with stage II and III rectal cancer underwent TME plus postoperative CRT (n = 309) or LPLD (n = 176). Patients in the postoperative CRT group received 8 cycles of 5-fluorouracil plus leucovorin and 45 Gy pelvic radiotherapy. Patients in the LPLD group underwent lateral lymph node dissection outside the pelvic plexus. The 5-year overall and disease-free survival rates were 78.3% and 67.3% in the postoperative CRT group, respectively, and 73.9% and 68.6% in the LPLD group, respectively, without significant differences between these groups. Patients in the LPLD group with stage III lower rectal cancer had a locoregional recurrence rate 2.2-fold greater than those in the postoperative CRT group (16.7% vs. 7.5%, P = 0.044). Multivariate analysis showed that APR and advanced T-category (T4) were significantly associated with locoregional recurrence, whereas lymph node metastases, high preoperative serum carcinoembryonic antigen, and APR were significantly associated with shortening of disease-free survival. Postoperative-CRT and LPLD following TME resulted in comparable survival rates, but the locoregional recurrence rate was higher in the LPLD group. These findings suggest that initial surgery is appropriate for rectal cancer patients who are candidates for low anterior resection without extensive local disease (T1–T3), regardless of lymph node status.Keywords
This publication has 33 references indexed in Scilit:
- Chemotherapy with Preoperative Radiotherapy in Rectal CancerNew England Journal of Medicine, 2006
- Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results—EORTC 22921Journal of Clinical Oncology, 2005
- Adjuvant Radiation for Rectal Cancer: Do We Measure Up to the Standard of Care? An Epidemiologic Analysis of Trends Over 25 Years in the United StatesDiseases of the Colon & Rectum, 2005
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004
- Adjuvant therapy is valuable in the treatment of rectal cancer despite total mesorectal excisionJournal of Surgical Oncology, 2003
- Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal CancerNew England Journal of Medicine, 2001
- Effect of a surgical training programme on outcome of rectal cancer in the County of StockholmThe Lancet, 2000
- Local recurrence of colorectal cancer: The problem, mechanisms, management and adjuvant therapyBritish Journal of Surgery, 1994
- Effective Surgical Adjuvant Therapy for High-Risk Rectal CarcinomaNew England Journal of Medicine, 1991
- Prolongation of the Disease-Free Interval in Surgically Treated Rectal CarcinomaNew England Journal of Medicine, 1985